UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.836

Sortiert nach

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization

Molecules (Basel, Switzerland), 2020-08, Vol.25 (17), p.3888

2020

Volltextzugriff (PDF)

Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease

American journal of respiratory and critical care medicine, 2017-05, Vol.195 (10), p.1333-1343

2017

Volltextzugriff (PDF)

Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery

Scientific reports, 2024-04, Vol.14 (1), p.9845-9845, Article 9845

2024

Volltextzugriff (PDF)

Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD

The European respiratory journal, 2017-10, Vol.50 (4), p.1700451-1700451

2017

Volltextzugriff (PDF)

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Molecules (Basel, Switzerland), 2022-06, Vol.27 (11), p.3619

2022

Volltextzugriff (PDF)

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Cochrane database of systematic reviews, 2015-11, Vol.2015 (11), p.CD007949

2015

Volltextzugriff (PDF)

Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols

International journal of pharmaceutics, 2024-05, Vol.656, p.124116-124116, Article 124116

2024

Volltextzugriff (PDF)

Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols

Analytical chemistry (Washington), 2020-06, Vol.92 (12), p.8323-8332

2020

Volltextzugriff (PDF)

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Cochrane database of systematic reviews, 2021-04, Vol.4 (4), p.CD007694-CD007694

2021

Volltextzugriff (PDF)

Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability

The AAPS journal, 2024-04, Vol.26 (3), p.56, Article 56

2024

Volltextzugriff (PDF)

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Journal of pharmaceutical sciences, 2017-03, Vol.106 (3), p.882-891

2017

Volltextzugriff (PDF)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Luminescence (Chichester, England), 2018-08, Vol.33 (5), p.913-918

2018

Volltextzugriff (PDF)

Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery

European journal of pharmaceutics and biopharmaceutics, 2015-10, Vol.96, p.132-142

2015

Volltextzugriff (PDF)

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects

Journal of aerosol medicine and pulmonary drug delivery, 2018-10, Vol.31 (5), p.290

2018

Volltextzugriff (PDF)

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Biopharmaceutics & drug disposition, 2017-10, Vol.38 (7), p.407-419

2017

Volltextzugriff (PDF)

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results

Health technology assessment (Winchester, England), 2021-08, Vol.25 (51), p.1-70

2021

Volltextzugriff (PDF)

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2015-10 (10), p.CD008989-CD008989

2015

Volltextzugriff (PDF)

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.673-682

Vauquelin, Georges

2016

Volltextzugriff (PDF)

Beta‑2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1

Molecular pharmaceutics, 2015-08, Vol.12 (8), p.2633-2641

2015

Volltextzugriff (PDF)

N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle

Antimicrobial agents and chemotherapy, 2016-11, Vol.60 (11), p.6709-6718

2016

Volltextzugriff (PDF)

Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

Pharmaceutical research, 2019-01, Vol.36 (1), p.15-14, Article 15

2019

Volltextzugriff (PDF)

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Advances in therapy, 2022-11, Vol.39 (11), p.4961-5010

2022

Volltextzugriff (PDF)

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Journal of periodontology (1970), 2017-07, Vol.88 (7), p.681-692

2017

Volltextzugriff (PDF)

Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging

Journal of aerosol medicine and pulmonary drug delivery, 2020-02, Vol.33 (1), p.43

2020

Volltextzugriff (PDF)

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Journal of pharmaceutical sciences, 2017-01, Vol.106 (1), p.313-321

2017

Volltextzugriff (PDF)

1 – 25 von 1.836

Suche als RSS-Feed

Aktive Filter

SpracheRumänisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.719)
Mit Volltextzugriff
(1.466)

Publikationsform

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Salmeterol Xinafoate
(1.702)
Albuterol - Analogs & Derivatives
(1.625)
Humans
(1.625)
Science & Technology
(1.261)
Life Sciences & Biomedicine
(1.231)
Male
(906)
Asthma - Drug Therapy
(903)
Female
(847)
Albuterol - Therapeutic Use
(836)
Albuterol - Administration & Dosage
(717)
Administration, Inhalation
(652)
Respiratory System
(648)
Adult
(641)
Middle Aged
(594)
Bronchodilator Agents - Therapeutic Use
(591)
Biological And Medical Sciences
(587)
Medical Sciences
(582)
Fluticasone
(531)
Bronchodilator Agents - Administration & Dosage
(483)
Salmeterol
(466)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization

Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease

Preclinical evaluation of novel synthesised nanoparticles based on tyrosine poly(ester amide) for improved targeted pulmonary delivery

Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD

Molecular Dynamic Study of Mechanism Underlying Nature of Molecular Recognition and the Role of Crosslinker in the Synthesis of Salmeterol-Targeting Molecularly Imprinted Polymer for Analysis of Salmeterol Xinafoate in Biological Fluid

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Nanoscale colocalized thermal and chemical mapping of pharmaceutical powder aerosols

Bulk to Nanometer-Scale Infrared Spectroscopy of Pharmaceutical Dry Powder Aerosols

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

Beta‑2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1

N-Desmethylclozapine, Fluoxetine, and Salmeterol Inhibit Postentry Stages of the Dengue Virus Life Cycle

Measuring The Bipolar Charge Distributions of Fine Particle Aerosol Clouds of Commercial PMDI Suspensions Using a Bipolar Next Generation Impactor (bp-NGI)

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Aktive Filter

Suchergebnisse filtern